KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Non-Current Assets: 2009-2025

Historic Other Non-Current Assets for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $270.8 million.

  • Biomarin Pharmaceutical's Other Non-Current Assets rose 35.86% to $270.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $270.8 million, marking a year-over-year increase of 35.86%. This contributed to the annual value of $251.4 million for FY2024, which is 46.55% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Other Non-Current Assets stood at $270.8 million for Q3 2025, which was up 8.66% from $249.2 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Other Non-Current Assets ranged from a high of $270.8 million in Q3 2025 and a low of $141.2 million during Q1 2021.
  • Its 3-year average for Other Non-Current Assets is $201.2 million, with a median of $190.8 million in 2024.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Other Non-Current Assets dropped by 5.03% in 2023 and then skyrocketed by 46.55% in 2024.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Other Non-Current Assets stood at $152.1 million in 2021, then increased by 15.85% to $176.2 million in 2022, then fell by 2.67% to $171.5 million in 2023, then surged by 46.55% to $251.4 million in 2024, then skyrocketed by 35.86% to $270.8 million in 2025.
  • Its Other Non-Current Assets stands at $270.8 million for Q3 2025, versus $249.2 million for Q2 2025 and $235.7 million for Q1 2025.